Catalent has entered an agreement to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.  The companies anticipate completing the transaction by the end of 2019, subject to regulatory approvals and customary closing conditions.    The Anagni plant has served as one of the primary launch facilities for BMS’ new medicines. Upon closing, Catalent will continue to manufacture BMS’ current product portfolio at the site.  ...